RxDoctor Payments Data

Alison Berlenbach

Family · Washington, DCNPI 1063187730

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 24.7% of the total. Among family clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,813in general payments, 2019–2025

Across 81 payments — averaging $34.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$694
  • Madrigal Pharmaceuticals$533
  • QOL Medical, LLC$386
  • Johnson & Johnson$185
  • Sanofi$183
  • Pfizer$141
  • plus $689 from 11 others

What the payments were for

  • Food & beverage$2,73697%
  • Education$773%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,813 in reported general payments places this provider in the 90th percentile of 392 family providers in District of Columbia.

See all family providers in District of Columbia

Medicare billing

Part B allowed, 2024
$36,916
Medicare patients
316
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates46$2,673
Famotidine33$702
Pantoprazole Sodium29$475
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl26$410

Paid to pharmacies, not to this prescriber.

Other family in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →